FDA ·
FDA import alerts are enforcement tools used at the border to detain drug products or ingredients without physical examination when the agency has reason to believe the goods are unapproved, adulterated, or misbranded. Throughout 2025 and 2026 FDA has issued a series of import alerts targeting Chinese and Indian API suppliers of GLP-1 peptides with inadequate regulatory documentation. These alerts effectively prevent the named suppliers' products from entering US commerce and have caused supply chain disruption for several compounding pharmacy networks.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.